Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative Pain
Go back to Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative Pain| TREVENA (NASDAQ: TRVN) | Delayed: 2.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.50 | 52 Week High | $13.02 | |||
| Open | $2.50 | 52 Week Low | $3.76 | |||
| Day High | $2.50 | P/E | N/A | |||
| Day Low | $2.50 | EPS | $-1.53 | |||
| Volume | 45 | |||||
